GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 208 filers reported holding GENMAB A/S in Q4 2021. The put-call ratio across all filers is 2.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $962,871 | -7.4% | 27,300 | -0.2% | 0.11% | -13.8% |
| Q2 2023 | $1,039,574 | +88.8% | 27,350 | +87.6% | 0.13% | +60.5% |
| Q1 2023 | $550,541 | +77.0% | 14,580 | +98.6% | 0.08% | +52.8% |
| Q4 2022 | $311,069 | +13.9% | 7,340 | -13.7% | 0.05% | -10.2% |
| Q3 2022 | $273,000 | -7.8% | 8,510 | -6.7% | 0.06% | -4.8% |
| Q2 2022 | $296,000 | -10.3% | 9,120 | 0.0% | 0.06% | +1.6% |
| Q1 2022 | $330,000 | -8.6% | 9,120 | 0.0% | 0.06% | -12.9% |
| Q4 2021 | $361,000 | -9.5% | 9,120 | 0.0% | 0.07% | -19.5% |
| Q3 2021 | $399,000 | +7.3% | 9,120 | 0.0% | 0.09% | +7.4% |
| Q2 2021 | $372,000 | +5.4% | 9,120 | +4.9% | 0.08% | -9.0% |
| Q4 2020 | $353,000 | +11.0% | 8,690 | 0.0% | 0.09% | -2.2% |
| Q3 2020 | $318,000 | +55.9% | 8,690 | +44.4% | 0.09% | +46.8% |
| Q2 2020 | $204,000 | – | 6,020 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |